
Brainify.AI turns EEG and multimodal brain data into objective biomarkers to guide diagnosis, predict treatment response, and support precision medicine across psychiatry, neurology, and neurodegeneration. The company operates a full‑stack B2B SaaS platform that combines a Foundational EEG AI model, a centralized Datahub aggregating clinics’ and research EEGs, and signal‑processing pipelines to produce trial‑ready biomarker packages and clinician reports. Core technologies include medical‑grade EEG hardware, deep learning and machine learning models, signal processing, and a data engine that continuously retrains on new partner data. Brainify.AI serves clinics, biopharma sponsors, and research institutions to improve clinical trial design, patient stratification, and diagnostic workflows at scale.

Brainify.AI turns EEG and multimodal brain data into objective biomarkers to guide diagnosis, predict treatment response, and support precision medicine across psychiatry, neurology, and neurodegeneration. The company operates a full‑stack B2B SaaS platform that combines a Foundational EEG AI model, a centralized Datahub aggregating clinics’ and research EEGs, and signal‑processing pipelines to produce trial‑ready biomarker packages and clinician reports. Core technologies include medical‑grade EEG hardware, deep learning and machine learning models, signal processing, and a data engine that continuously retrains on new partner data. Brainify.AI serves clinics, biopharma sponsors, and research institutions to improve clinical trial design, patient stratification, and diagnostic workflows at scale.
Sector: Neurotechnology / Biotechnology (EEG AI and precision neuroscience)
Founded: 2021
Founders: Mariam Khayretdinova (CEO), Ivan Mishanin (COO)
Business model: B2B SaaS platform serving clinics, biopharma sponsors, and research institutions
Core tech: Foundational EEG AI model, dataset hub, signal-processing pipelines, medical-grade EEG hardware
Notable investors: Merck GHI / Merck Digital Sciences Studio; Northpond Ventures; McKesson; Kodori
Objective brain biomarkers for diagnosis, treatment response prediction, and precision medicine in psychiatry, neurology, and neurodegeneration.
2021
Biotechnology
Crunchbase records multiple pre‑seed rounds with latest announced on Oct 1, 2023.
4050000
Most recent disclosed funding date and total funding amount reported on company snapshot.
“Merck GHI / Merck Digital Sciences Studio, Northpond Ventures, McKesson, Kodori”